Allergan (NYSE:AGN) received a $265.00 price target from stock analysts at JPMorgan Chase in a research report issued on Thursday, March 15th. The firm presently has a “buy” rating on the stock. JPMorgan Chase’s price target would indicate a potential upside of 64.07% from the company’s previous close.
A number of other research analysts also recently weighed in on AGN. Leerink Swann reissued an “outperform” rating and issued a $237.00 price objective on shares of Allergan in a research note on Monday, November 27th. Morgan Stanley raised Allergan from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $171.92 to $200.00 in a research report on Wednesday, November 29th. Cantor Fitzgerald set a $191.00 price target on Allergan and gave the stock a “hold” rating in a research report on Saturday, December 2nd. TheStreet downgraded Allergan from a “c-” rating to a “d+” rating in a research report on Monday, December 4th. Finally, Wells Fargo reaffirmed a “buy” rating on shares of Allergan in a research report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Allergan has a consensus rating of “Buy” and an average target price of $224.02.
Shares of AGN stock traded down $3.61 during trading on Thursday, reaching $161.52. The company had a trading volume of 2,105,830 shares, compared to its average volume of 2,920,951. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16. Allergan has a one year low of $142.81 and a one year high of $256.80. The company has a market capitalization of $57,521.17, a price-to-earnings ratio of 9.88, a PEG ratio of 1.18 and a beta of 1.18.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The business had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. During the same period last year, the business earned $3.90 EPS. The firm’s revenue was up 12.0% compared to the same quarter last year. analysts forecast that Allergan will post 15.58 EPS for the current fiscal year.
In related news, insider Maria Teresa Hilado purchased 895 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average price of $167.39 per share, with a total value of $149,814.05. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Joseph H. Boccuzi purchased 900 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The stock was bought at an average cost of $143.42 per share, for a total transaction of $129,078.00. The disclosure for this purchase can be found here. Insiders have bought a total of 8,095 shares of company stock worth $1,258,081 in the last three months. 0.36% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in the stock. KCM Investment Advisors LLC boosted its stake in Allergan by 13.4% in the 4th quarter. KCM Investment Advisors LLC now owns 38,335 shares of the company’s stock valued at $6,271,000 after buying an additional 4,539 shares in the last quarter. Colonial Trust Advisors acquired a new position in Allergan in the fourth quarter worth $470,000. Penbrook Management LLC acquired a new position in Allergan in the fourth quarter worth $978,000. Massmutual Trust Co. FSB ADV boosted its stake in Allergan by 6.9% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 15,342 shares of the company’s stock worth $16,161,000 after purchasing an additional 994 shares in the last quarter. Finally, Pin Oak Investment Advisors Inc. acquired a new position in Allergan in the fourth quarter worth $1,787,000. 77.97% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/allergan-agn-given-a-265-00-price-target-at-jpmorgan-chase-co.html.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.